Marcel Jaspars, Professor of Organic Chemistry together with Prof Jim Naismith at the University of Oxford and Dr Bill Primrose, Entrepreneur, have spun out GyreOx Therapeutics with funding from Innovate UK and other investors. This funding will allow GyreOx to employ three scientists and engage consultants when necessary for a period of 2 years to raise additional investment.
Marcel Jaspars, Professor of Organic Chemistry together with Prof Jim Naismith at the University of Oxford and Dr Bill Primrose, Entrepreneur, have spun out GyreOx Therapeutics with funding from Innovate UK and other investors. This funding will allow GyreOx to employ three scientists and engage consultants when necessary for a period of 2 years to raise additional investment.
GyreOx will use an automated chemoenzymatic process to treat complex diseases by producing designed compound libraries to hit ‘undruggable’ targets. The GyreOx combination of computational design, automation and unique engineered enzymes allows them to deliver novel drugs in the chemical space beyond the 'rule of 5'. Focussed library design enables better compound-target interaction and the tuning of important drug properties. No other technology offers GyreOx's degree of flexibility in design and production.